Episode Details

Hosts: Dr. Daniel Ennis, Dr. Janet Pope

Guests: Dr. Marinka Twilt (Pediatric Rheumatologist, University of Calgary; ASM Program Committee Chair), Dr. Mo Osman (University of Alberta; Abstract Chair & ASM Planning Committee Co-Chair)

We’re coming to you almost live from Halifax for Day 2 of the Canadian Rheumatology Association ASM. The day featured diverse podium science, practical workshops, and a lively Great Debate on DMARD tapering.

Podium sessions highlighted lupus research on cancer risk, rising costs and work disability in RA, and new biologic insights into flares, with B-cell changes supporting patient-reported disease activity in lupus.

Workshops focused on practical tools, including capillaroscopy for early CTD detection, pediatric updates on neonatal lupus risk (anti-Ro vs anti-La), and a structured lab-based approach to unexplained lymphadenopathy.

The Dunlop-Dottridge Lecture reviewed statin-associated myositis, emphasizing delayed onset, persistence after discontinuation of the statins, and early IVIG-based treatment.

The Great Debate explored DMARD tapering, reinforcing that while guidelines are cautious, real-world care requires shared decision-making and a focus on the lowest effective dose rather than full discontinuation.

Main Takeaways

Rising costs and ongoing work disability remain significant in RA

Patient-reported flares have a clear biological basis

Statin-associated myositis can occur years after statin use and requires early IVIG

DMARD tapering should be individualized, with focus on lowest effective dose

What to Watch for on Day 3

State-of-the-art lecture on Still’s disease across the lifespan

More high-impact podium presentations

Clinical workshops, including one on topical therapies

Gala dinner and closing events

More highlights coming tomorrow—stay tuned!